Identification

Name
Decitabine
Accession Number
DB01262
Type
Small Molecule
Groups
Approved, Investigational
Description

Decitabine is indicated for treatment of patients with myelodysplastic syndrome (MDS). It is a chemical analogue of cytidine, a nucleoside present in DNA and RNA. Cells in the presence of Decitabine incorporate it into DNA during replication and RNA during transcription. The incorporation of Decitabine into DNA or RNA inhibits methyltransferase thereby causing demethylation in that sequence. This adversely affects the way that cell regulatory proteins are able to bind to the DNA/RNA substrate.

Structure
Thumb
Synonyms
  • 4-amino-1-(2-Deoxy-beta-D-erythro-pentofuranosyl)-S-triazin-2(1H)-one
  • 5-aza-2'-deoxycytidine
  • 5-Azadeoxycytidine
  • Azadc
  • Decitabine
  • Dezocitidine
External IDs
NSC-127716
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
DacogenInjection, powder, lyophilized, for solution50 mg/20mLIntravenousEisai Limited1996-05-032018-12-31Us
DacogenInjection, powder, for solution50 mgIntravenousJanssen Cilag International Nv2012-09-20Not applicableEu
DacogenInjection, powder, lyophilized, for solution50 mg/20mLIntravenousOtsuka Pharmaceutical Co., Ltd.1996-05-03Not applicableUs
DecitabineKitSun Pharma Global FZE2014-01-24Not applicableUs
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
DecitabineInjection, powder, lyophilized, for solution50 mg/50mLIntravenousDr Reddy's Laboratories2013-07-11Not applicableUs
DecitabineInjection, powder, lyophilized, for solution50 mg/50mLIntravenousSandoz2014-08-28Not applicableUs
DecitabineInjection, powder, lyophilized, for solution50 mg/50mLIntravenousDr Reddy's Laboratories2014-12-05Not applicableUs
DecitabineInjection, powder, lyophilized, for solution50 mg/20mLIntravenousAccord Healthcare Limited2017-03-08Not applicableUs
DecitabineInjection, powder, lyophilized, for solution50 mg/50mLIntravenousDr Reddy's Laboratories2013-07-11Not applicableUs
Categories
UNII
776B62CQ27
CAS number
2353-33-5
Weight
Average: 228.2053
Monoisotopic: 228.085854892
Chemical Formula
C8H12N4O4
InChI Key
XAUDJQYHKZQPEU-KVQBGUIXSA-N
InChI
InChI=1S/C8H12N4O4/c9-7-10-3-12(8(15)11-7)6-1-4(14)5(2-13)16-6/h3-6,13-14H,1-2H2,(H2,9,11,15)/t4-,5+,6+/m0/s1
IUPAC Name
4-amino-1-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,2-dihydro-1,3,5-triazin-2-one
SMILES
NC1=NC(=O)N(C=N1)[[email protected]]1C[[email protected]](O)[[email protected]@H](CO)O1

Pharmacology

Indication

For treatment of patients with myelodysplastic syndromes (MDS) including previously treated and untreated, de novo and secondary MDS of all French-American-British subtypes (refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, and chronic myelomonocytic leukemia) and intermediate-1, intermediate-2, and high-risk International Prognostic Scoring System groups (scores ≥0.5).

Structured Indications
Pharmacodynamics

Decitabine is an analogue of the natural nucleoside 2’-deoxycytidine. It functions in the same way as 5-Azacytidine. The antineoplastic activity of this drug is dependent on its intracellular conversion to its 5'-triphosphate metabolite.

Mechanism of action

Decitabine is believed to exert its antineoplastic effects following its conversion to decitabine triphosphate, where the drug directly incorporates into DNA and inhibits DNA methyltransferase, the enzyme that is responsible for methylating newly synthesized DNA in mammalian cells. This results in hypomethylation of DNA and cellular differentiation or apoptosis. Decitabine inhibits DNA methylation in vitro, which is achieved at concentrations that do not cause major suppression of DNA synthesis. Decitabine-induced hypomethylation in neoplastic cells may restore normal function to genes that are critical for the control of cellular differentiation and proliferation. In rapidly dividing cells, the cytotoxicity of decitabine may also be attributed to the formation of covalent adducts between DNA methyltransferase and decitabine that has been incorporated into DNA. Non-proliferating cells are relatively insensitive to decitabine. Decitabine is cell cycle specific and acts peripherally in the S phase of the cell cycle. It does not inhibit the progression of cells from the G1 to S phase.

TargetActionsOrganism
ADNA
other/unknown
Human
ADNA (cytosine-5)-methyltransferase 1
inhibitor
Human
Absorption
Not Available
Volume of distribution
Not Available
Protein binding

Plasma protein binding of decitabine is negligible (<1%).

Metabolism

The exact route of elimination and metabolic fate of decitabine is not known in humans. One of the pathways of elimination of decitabine appears to be deamination by cytidine deaminase found principally in the liver but also in granulocytes, intestinal epithelium and whole blood.

Route of elimination
Not Available
Half life

The terminal phase elimination half-life is 0.51 ± 0.31 hours.

Clearance
  • 125 L/h/m2 [Patients receiving 15 mg/m2 3-hr infusion every 8 hours for 3 days]
  • 210 L/h/m2 [20 mg/m2 1-hr infusion daily for 5 days]
Toxicity

There is no known antidote for overdosage with decitabine. Higher doses are associated with increased myelosuppression including prolonged neutropenia and thrombocytopenia.

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Decitabine.Approved
AcetyldigoxinAcetyldigoxin may decrease the cardiotoxic activities of Decitabine.Experimental
BCG vaccineThe therapeutic efficacy of BCG vaccine can be decreased when used in combination with Decitabine.Investigational
BevacizumabBevacizumab may increase the cardiotoxic activities of Decitabine.Approved, Investigational
CabazitaxelThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Decitabine.Approved
ClozapineThe risk or severity of adverse effects can be increased when Decitabine is combined with Clozapine.Approved
CyclophosphamideCyclophosphamide may increase the cardiotoxic activities of Decitabine.Approved, Investigational
CymarinCymarin may decrease the cardiotoxic activities of Decitabine.Experimental
DeslanosideDeslanoside may decrease the cardiotoxic activities of Decitabine.Approved
DigitoxinDigitoxin may decrease the cardiotoxic activities of Decitabine.Approved, Investigational
DigoxinDigoxin may decrease the cardiotoxic activities of Decitabine.Approved
DocetaxelThe risk or severity of adverse effects can be increased when Docetaxel is combined with Decitabine.Approved, Investigational
GitoformateGitoformate may decrease the cardiotoxic activities of Decitabine.Experimental
Lanatoside CLanatoside C may decrease the cardiotoxic activities of Decitabine.Experimental
MetamizoleThe risk or severity of adverse effects can be increased when Metamizole is combined with Decitabine.Investigational, Withdrawn
MetildigoxinMetildigoxin may decrease the cardiotoxic activities of Decitabine.Experimental
OleandrinOleandrin may decrease the cardiotoxic activities of Decitabine.Experimental, Investigational
OuabainOuabain may decrease the cardiotoxic activities of Decitabine.Approved
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Decitabine.Approved, Vet Approved
PeruvosidePeruvoside may decrease the cardiotoxic activities of Decitabine.Experimental
ProscillaridinProscillaridin may decrease the cardiotoxic activities of Decitabine.Experimental
TrastuzumabTrastuzumab may increase the cardiotoxic activities of Decitabine.Approved, Investigational
Food Interactions
Not Available

References

Synthesis Reference

Julian Paul Henschke, Xiaoheng Zhang, Jianbo Yu, Kun Hu, Lijun Mei, "Synthesis of Decitabine." U.S. Patent US20100087637, issued April 08, 2010.

US20100087637
General References
  1. Appleton K, Mackay HJ, Judson I, Plumb JA, McCormick C, Strathdee G, Lee C, Barrett S, Reade S, Jadayel D, Tang A, Bellenger K, Mackay L, Setanoians A, Schatzlein A, Twelves C, Kaye SB, Brown R: Phase I and pharmacodynamic trial of the DNA methyltransferase inhibitor decitabine and carboplatin in solid tumors. J Clin Oncol. 2007 Oct 10;25(29):4603-9. [PubMed:17925555]
  2. Wijermans PW, Ruter B, Baer MR, Slack JL, Saba HI, Lubbert M: Efficacy of decitabine in the treatment of patients with chronic myelomonocytic leukemia (CMML). Leuk Res. 2008 Apr;32(4):587-91. Epub 2007 Sep 18. [PubMed:17881052]
  3. Daskalakis M, Blagitko-Dorfs N, Hackanson B: Decitabine. Recent Results Cancer Res. 2010;184:131-57. doi: 10.1007/978-3-642-01222-8_10. [PubMed:20072836]
  4. Saba HI, Wijermans PW: Decitabine in myelodysplastic syndromes. Semin Hematol. 2005 Jul;42(3 Suppl 2):S23-31. [PubMed:16015501]
  5. Jabbour E, Issa JP, Garcia-Manero G, Kantarjian H: Evolution of decitabine development: accomplishments, ongoing investigations, and future strategies. Cancer. 2008 Jun;112(11):2341-51. doi: 10.1002/cncr.23463. [PubMed:18398832]
  6. Stresemann C, Lyko F: Modes of action of the DNA methyltransferase inhibitors azacytidine and decitabine. Int J Cancer. 2008 Jul 1;123(1):8-13. doi: 10.1002/ijc.23607. [PubMed:18425818]
  7. Oki Y, Aoki E, Issa JP: Decitabine--bedside to bench. Crit Rev Oncol Hematol. 2007 Feb;61(2):140-52. Epub 2006 Oct 4. [PubMed:17023173]
External Links
Human Metabolome Database
HMDB15391
KEGG Drug
D03665
PubChem Compound
451668
PubChem Substance
46505657
ChemSpider
397844
BindingDB
96274
ChEBI
50131
ChEMBL
CHEMBL1201129
Therapeutic Targets Database
DAP000641
PharmGKB
PA164749631
Drugs.com
Drugs.com Drug Page
Wikipedia
Decitabine
ATC Codes
L01BC08 — Decitabine
FDA label
Download (100 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0Active Not RecruitingTreatmentPancreatic Adenocarcinoma Metastatic1
0RecruitingTreatmentAggressive B-cell Lymphoma / Indolent B-cell Lymphoma / Non-Hodgkin's Lymphoma (NHL) / T-Cell Lymphomas1
1Active Not RecruitingTreatmentAcute Myelogenous Leukaemia (AML) / Myelogenous Leukemia / Treatment Naive AML1
1Active Not RecruitingTreatmentAdult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Del(5q) / Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) / Adult Acute Myeloid Leukemia With T(15;17)(q22;q12) / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Acute Myeloid Leukemia With T(8;21)(q22;q22) / Recurrent Adult Acute Myeloid Leukemia / Recurrent Childhood Acute Myeloid Leukemia / Secondary Acute Myeloid Leukemia / Untreated Adult Acute Myeloid Leukemia1
1Active Not RecruitingTreatmentAdvanced Breast Cancer1
1Active Not RecruitingTreatmentChronic Myelomonocytic Leukemia / De Novo Myelodysplastic Syndrome / Essential Thrombocythemia (ET) / Myelodysplastic Syndrome / Myelodysplastic/Myeloproliferative Neoplasms / Polycythemia Vera (PV) / Previously Treated Myelodysplastic Syndromes / Primary Myelofibrosis / Recurrent Adult Acute Myeloid Leukemia / Recurrent Childhood Acute Myeloid Leukemia / Untreated Adult Acute Myeloid Leukemia1
1Active Not RecruitingTreatmentHematopoetic Myelodysplasia / Leukemia Acute Myeloid Leukemia (AML) / Leukemia, Lymphoblastic, Acute1
1Active Not RecruitingTreatmentLeukemia Acute Myeloid Leukemia (AML)2
1Active Not RecruitingTreatmentLeukemia Acute Myeloid Leukemia (AML) / Myelodysplastic Syndrome1
1Active Not RecruitingTreatmentLeukemia Acute Myeloid Leukemia (AML) / Recurrent Adult Acute Myeloid Leukemia / Secondary Acute Myeloid Leukemia / Therapy-Related Acute Myeloid Leukemia / Untreated Adult Acute Myeloid Leukemia1
1Active Not RecruitingTreatmentLeukemia Acute Myeloid Leukemia (AML) / Secondary Acute Myeloid Leukemia / Untreated Adult Acute Myeloid Leukemia1
1CompletedTreatmentAcute Lymphocytic Leukemia (ALL)1
1CompletedTreatmentAdult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Del(5q) / Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) / Adult Acute Myeloid Leukemia With T(15;17)(q22;q12) / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Acute Myeloid Leukemia With T(8;21)(q22;q22) / Chronic Myelomonocytic Leukemia / Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable / Philadelphia Chromosome Negative Chronic Myelogenous Leukemia / Previously Treated Myelodysplastic Syndromes / Recurrent Adult Acute Lymphoblastic Leukemia / Recurrent Adult Acute Myeloid Leukemia / Relapsing Chronic Myelogenous Leukemia1
1CompletedTreatmentAdult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Del(5q) / Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) / Adult Acute Myeloid Leukemia With T(15;17)(q22;q12) / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Acute Myeloid Leukemia With T(8;21)(q22;q22) / Recurrent Adult Acute Myeloid Leukemia / Recurrent Small Lymphocytic Lymphoma / Refractory Chronic Lymphocytic Leukemia / Untreated Adult Acute Myeloid Leukemia1
1CompletedTreatmentAdult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) / Adult Acute Myeloid Leukemia With T(15;17)(q22;q12) / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Acute Myeloid Leukemia With T(8;21)(q22;q22) / Blastic Phase Chronic Myelogenous Leukemia / Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue / Nodal marginal zone B-cell lymphomas / Recurrent Adult Acute Lymphoblastic Leukemia / Recurrent Adult Acute Myeloid Leukemia / Recurrent Adult Burkitt Lymphoma / Recurrent Adult Diffuse Large Cell Lymphoma / Recurrent Adult Diffuse Mixed Cell Lymphoma / Recurrent Adult Diffuse Small Cleaved Cell Lymphoma / Recurrent Adult Immunoblastic Large Cell Lymphoma / Recurrent Adult Lymphoblastic Lymphoma / Recurrent Grade 1 Follicular Lymphoma / Recurrent Grade 2 Follicular Lymphoma / Recurrent Grade 3 Follicular Lymphoma / Recurrent Mantle Cell Lymphoma / Recurrent Marginal Zone Lymphoma / Recurrent Small Lymphocytic Lymphoma / Secondary Acute Myeloid Leukemia / Splenic Marginal Zone Lymphoma / Stage III Adult Burkitt Lymphoma / Stage III Adult Diffuse Large Cell Lymphoma / Stage III Adult Diffuse Mixed Cell Lymphoma / Stage III Adult Diffuse Small Cleaved Cell Lymphoma / Stage III Adult Immunoblastic Large Cell Lymphoma / Stage III Adult Lymphoblastic Lymphoma / Stage III Grade 1 Follicular Lymphoma / Stage III Grade 2 Follicular Lymphoma / Stage III Grade 3 Follicular Lymphoma / Stage III Mantle Cell Lymphoma / Stage III Marginal Zone Lymphoma / Stage III Small Lymphocytic Lymphoma / Stage IV Adult Burkitt Lymphoma / Stage IV Adult Diffuse Large Cell Lymphoma / Stage IV Adult Diffuse Mixed Cell Lymphoma / Stage IV Adult Diffuse Small Cleaved Cell Lymphoma / Stage IV Adult Immunoblastic Large Cell Lymphoma / Stage IV Adult Lymphoblastic Lymphoma / Stage IV Grade 1 Follicular Lymphoma / Stage IV Grade 2 Follicular Lymphoma / Stage IV Grade 3 Follicular Lymphoma / Stage IV Mantle Cell Lymphoma / Stage IV Marginal Zone Lymphoma / Stage IV Small Lymphocytic Lymphoma / Unspecified Adult Solid Tumor, Protocol Specific / Untreated Adult Acute Lymphoblastic Leukemia / Untreated Adult Acute Myeloid Leukemia1
1CompletedTreatmentAdult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) / Adult Acute Myeloid Leukemia With T(15;17)(q22;q12) / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Acute Myeloid Leukemia With T(8;21)(q22;q22) / Recurrent Adult Acute Myeloid Leukemia / Secondary Acute Myeloid Leukemia / Untreated Adult Acute Myeloid Leukemia1
1CompletedTreatmentAdult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11 / Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11 / Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); RUNX1-RUNX1T1 / Adult Acute Myeloid Leukemia With t(9;11)(p22;q23); MLLT3-MLL / Adult Acute Promyelocytic Leukemia With t(15;17)(q22;q12); PML-RARA / Alkylating Agent-Related Acute Myeloid Leukemia / Previously Treated Myelodysplastic Syndromes / Recurrent Adult Acute Myeloid Leukemia / Refractory Acute Myeloid Leukemia / Secondary Acute Myeloid Leukemia / Therapy-Related Acute Myeloid Leukemia / Untreated Adult Acute Myeloid Leukemia1
1CompletedTreatmentAdvanced Esophageal Cancers / Cancers of Non-thoracic Origin With Metastases to the Lungs or Pleura / Lung Cancer Non-Small Cell Cancer (NSCLC) / Pleural Mesotheliomas / Primary Small Cell Lung Cancers1
1CompletedTreatmentAlkylating Agent-Related Acute Myeloid Leukemia / Chronic Myelomonocytic Leukemia / Leukemia Acute Myeloid Leukemia (AML) / Myelodysplastic Syndrome / Refractory Anemia With Excess Blasts in Transformation1
1CompletedTreatmentChronic Myeloproliferative Disorders / Leukemias / Malignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes / Precancerous Conditions / Unspecified Adult Solid Tumor, Protocol Specific1
1CompletedTreatmentChronic Myeloproliferative Disorders / Leukemias / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Neoplasms1
1CompletedTreatmentColorectal Cancers1
1CompletedTreatmentEsophageal Cancers / Lung Cancers / Mesothelioma, Malignant / Metastatic Cancers1
1CompletedTreatmentLeukemia Acute Myeloid Leukemia (AML)5
1CompletedTreatmentLeukemia Acute Myeloid Leukemia (AML) / Myelodysplastic Syndromes1
1CompletedTreatmentLeukemia, Myelocytic, Acute Myelodysplastic Syndromes / Myelodysplastic Syndromes1
1CompletedTreatmentLeukemias1
1CompletedTreatmentMale Breast Cancer / Recurrent Bladder Cancer / Recurrent Breast Cancer / Recurrent Melanoma / Stage III Melanoma / Stage IV Bladder Cancer / Stage IV Breast Cancer / Stage IV Melanoma / Unspecified Adult Solid Tumor, Protocol Specific1
1CompletedTreatmentMelanoma1
1CompletedTreatmentMyelodysplastic Syndrome2
1CompletedTreatmentMyelodysplastic Syndromes1
1CompletedTreatmentMyelodysplastic Syndromes and Leukemia, Myeloid, Acute1
1CompletedTreatmentRecurrent Adult Burkitt Lymphoma / Recurrent Adult Diffuse Large Cell Lymphoma / Recurrent Mantle Cell Lymphoma1
1CompletedTreatmentRecurrent Fallopian Tube Cancer / Recurrent Ovarian Epithelial Cancer / Recurrent Primary Peritoneal Cavity Cancer1
1CompletedTreatmentRecurrent Neuroblastoma / Unspecified Childhood Solid Tumor, Protocol Specific1
1CompletedTreatmentRecurrent Non-small Cell Lung Cancer / Stage IV Non-Small Cell Lung Cancer1
1Not Yet RecruitingTreatmentAgnogenic Myeloid Metaplasia / Atypical Chronic Myeloid Leukemia / Chronic Myelomonocytic Leukemia / Juvenile Myelomonocytic Leukemia / Myelodysplastic Syndromes / Myeloproliferative Neoplasms1
1Not Yet RecruitingTreatmentFallopian Tube Carcinoma / Ovarian Carcinoma / Primary Peritoneal Cancer / Recurrent Fallopian Tube Carcinoma / Recurrent Ovarian Carcinoma / Recurrent Primary Peritoneal Carcinoma1
1RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL) / Hematopoietic/Lymphoid Cancer / Leukemia Acute Myeloid Leukemia (AML)1
1RecruitingTreatmentBone Marrow Diseases / Hematologic Diseases / Leukemia Acute Myeloid Leukemia (AML) / Leukemias / Myelodysplastic Syndrome / Myelodysplastic Syndromes / Myeloid Leukemias1
1RecruitingTreatmentChimerism / Hematopoietic Cell Transplantation Recipient / Leukemia Acute Myeloid Leukemia (AML) / Myelodysplastic Syndrome / Myelodysplastic Syndrome With Excess Blasts-1 / Myelodysplastic Syndrome With Excess Blasts-2 / Previously Treated Myelodysplastic Syndromes / Recurrent Acute Myeloid Leukemia With Myelodysplasia-Related Changes / Recurrent Adult Acute Myeloid Leukemia / Secondary Acute Myeloid Leukemia / Untreated Adult Acute Myeloid Leukemia1
1RecruitingTreatmentLeukemia Acute Myeloid Leukemia (AML)1
1RecruitingTreatmentLeukemia Acute Myeloid Leukemia (AML) / Recurrent Adult Acute Myeloid Leukemia / Secondary Acute Myeloid Leukemia / TP53 wt Allele / Untreated Adult Acute Myeloid Leukemia1
1RecruitingTreatmentLeukemia Acute Myeloid Leukemia (AML) / Untreated Adult Acute Myeloid Leukemia1
1RecruitingTreatmentDe Novo Myelodysplastic Syndrome / Mixed Phenotype Acute Leukemia (MPAL) / Previously Treated Myelodysplastic Syndromes / Recurrent Adult Acute Myeloid Leukemia / Recurrent High Risk Myelodysplastic Syndrome / Refractory Acute Myeloid Leukemia / Refractory High Risk Myelodysplastic Syndrome / Untreated Adult Acute Myeloid Leukemia1
1RecruitingTreatmentPancreatic Ductal Adenocarcinoma / Sarcomas1
1RecruitingTreatmentRecurrent Adult Acute Myeloid Leukemia / Recurrent Childhood Acute Myeloid Leukemia / Refractory Acute Myeloid Leukemia / Secondary Acute Myeloid Leukemia / Therapy-Related Acute Myeloid Leukemia / Untreated Adult Acute Myeloid Leukemia1
1SuspendedTreatmentRecurrent Adult Acute Myeloid Leukemia / Secondary Acute Myeloid Leukemia / Therapy-Related Acute Myeloid Leukemia / Untreated Adult Acute Myeloid Leukemia1
1TerminatedTreatmentAdult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) / Adult Acute Myeloid Leukemia With T(15;17)(q22;q12) / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Acute Myeloid Leukemia With T(8;21)(q22;q22) / Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative / De Novo Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable / Previously Treated Myelodysplastic Syndromes / Recurrent Adult Acute Myeloid Leukemia / Secondary Acute Myeloid Leukemia / Secondary Myelodysplastic Syndromes / Untreated Adult Acute Myeloid Leukemia1
1TerminatedTreatmentCancers1
1TerminatedTreatmentChildhood Acute Myeloblastic Leukemia With Maturation (M2) / Childhood Acute Promyelocytic Leukemia (M3) / Recurrent Childhood Acute Lymphoblastic Leukemia / Recurrent Childhood Acute Myeloid Leukemia / Secondary Acute Myeloid Leukemia1
1TerminatedTreatmentHematopoietic/Lymphoid Cancer / Unspecified Adult Solid Tumor, Protocol Specific1
1TerminatedTreatmentLeukemias1
1TerminatedTreatmentMyelodysplastic Syndrome1
1TerminatedTreatmentUnspecified Adult Solid Tumor, Protocol Specific1
1WithdrawnTreatmentMelanoma / Neoplasms Metastasis / Neoplasms, Germ Cell and Embryonal / Sarcomas1
1, 2Active Not RecruitingTreatmentLeukemias1
1, 2Active Not RecruitingTreatmentMyelodysplastic Syndromes1
1, 2Active Not RecruitingTreatmentMyelodysplastic Syndrome / Smith-Magenis Syndrome1
1, 2Active Not RecruitingTreatmentPreviously Treated Myelodysplastic Syndromes / Recurrent Adult Acute Myeloid Leukemia1
1, 2CompletedTreatmentCancer, Ovarian1
1, 2CompletedTreatmentChronic Myelomonocytic Leukemia / De Novo Myelodysplastic Syndromes / Myelodysplastic Syndromes / Refractory Anemia / Refractory Anemia With Excess Blasts / Refractory Anemia With Ringed Sideroblasts / Refractory Cytopenia With Multilineage Dysplasia / Thrombocytopenias1
1, 2CompletedTreatmentColorectal Cancers / Liver Metastasis1
1, 2CompletedTreatmentLeukemia Acute Myeloid Leukemia (AML) / Myelodysplastic Syndromes1
1, 2CompletedTreatmentLeukemia Acute Myeloid Leukemia (AML) / Smith-Magenis Syndrome1
1, 2CompletedTreatmentLeukemias1
1, 2CompletedTreatmentLeukemias / Myelodysplastic Syndromes2
1, 2CompletedTreatmentMalignant Melanoma1
1, 2CompletedTreatmentMetastatic Melanoma1
1, 2CompletedTreatmentMyelodysplastic Syndromes1
1, 2Not Yet RecruitingTreatmentLeukemia Acute Myeloid Leukemia (AML)2
1, 2Not Yet RecruitingTreatmentLeukemia Acute Myeloid Leukemia (AML) / Myelodysplastic Syndromes1
1, 2Not Yet RecruitingTreatmentMyelodysplastic Syndromes1
1, 2RecruitingTreatmentAcute Myelogenous Leukaemia (AML)1
1, 2RecruitingTreatmentAcute Myeloid Leukemia, in Relapse / Recurrent Adult Acute Myeloid Leukemia1
1, 2RecruitingTreatmentBRAF-mutated Metastatic Melanoma / Melanoma / Metastatic Melanoma / V600EBRAF-mutated Metastatic Melanoma1
1, 2RecruitingTreatmentCancers1
1, 2RecruitingTreatmentLeukemia Acute Myeloid Leukemia (AML)2
1, 2RecruitingTreatmentLeukemia Acute Myeloid Leukemia (AML) / Myelodysplastic Syndromes1
1, 2RecruitingTreatmentLeukemias2
1, 2RecruitingTreatmentLeukemias / Myeloproliferative Disorders1
1, 2RecruitingTreatmentLung Cancer Non-Small Cell Cancer (NSCLC) / Lung Cancers1
1, 2RecruitingTreatmentLymphoma, B Cell / Tumors, Solid1
1, 2RecruitingTreatmentLymphoma, Hodgkins1
1, 2RecruitingTreatmentLymphoma, Large B-Cell, Diffuse (DLBCL)1
1, 2RecruitingTreatmentMalignancies Multiple1
1, 2RecruitingTreatmentMyeloproliferative Neoplasms1
1, 2RecruitingTreatmentRecurrent Adult Acute Myeloid Leukemia1
1, 2RecruitingTreatmentRelapsed Acute Myeloid Leukemia1
1, 2TerminatedTreatmentAcute Lymphoblastic Leukaemias (ALL) / Precursor B-Cell Lymphoblastic Leukemia / Precursor T-Cell Lymphoblastic Leukemia1
1, 2TerminatedTreatmentCancer, Breast / Neoplasms, Breast / Tumors, Breast1
1, 2TerminatedTreatmentGliomas / Medulloblastomas / Neuroectodermal Tumors, Primitive1
1, 2Unknown StatusTreatmentLeukemia Acute Myeloid Leukemia (AML)1
2Active Not RecruitingPreventionLeukemia Acute Myeloid Leukemia (AML)1
2Active Not RecruitingTreatmentAcute Myeloid Leukemia (AML) With Multilineage Dysplasia Following Myelodysplastic Syndrome, in Adults / Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome / Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Del(5q) / Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Acute Myeloid Leukemia With T(8;21)(q22;q22) / AML (Adult) With 11q23 (MLL) Abnormalities / AML (Adult) With Del(5q) / AML (Adult) With Inv(16)(p13;q22) / AML (Adult) With t(16;16)(p13;q22) / AML (Adult) With t(8;21)(q22;q22) / Secondary Acute Myeloid Leukemia / Secondary AML (Adult) / Untreated Adult Acute Myeloid Leukemia / Untreated AML (Adult)1
2Active Not RecruitingTreatmentAcute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome / Adult Acute Megakaryoblastic Leukemia / Adult Acute Monoblastic Leukemia / Adult Acute Monocytic Leukemia / Adult Acute Myeloid Leukemia With Minimal Differentiation / Adult Acute Myeloid Leukemia With t(9;11)(p22;q23); MLLT3-MLL / Adult Acute Myeloid Leukemia Without Maturation / Adult Erythroleukemia / Adult Pure Erythroid Leukemia / Alkylating Agent-Related Acute Myeloid Leukemia / Leukemia Acute Myeloid Leukemia (AML) / Secondary Acute Myeloid Leukemia / Therapy-Related Acute Myeloid Leukemia / Untreated Adult Acute Myeloid Leukemia1
2Active Not RecruitingTreatmentAcute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome / Adult Acute Myeloid Leukemia in Remission / Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Del(5q) / Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) / Adult Acute Myeloid Leukemia With T(15;17)(q22;q12) / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Acute Myeloid Leukemia With T(8;21)(q22;q22) / De Novo Myelodysplastic Syndromes / Previously Treated Myelodysplastic Syndromes / Recurrent Adult Acute Myeloid Leukemia / Secondary Acute Myeloid Leukemia1
2Active Not RecruitingTreatmentAcute Myeloid Leukemia With Myelodysplasia-Related Changes / Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11 / Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11 / Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); RUNX1-RUNX1T1 / Adult Acute Myeloid Leukemia With t(8;21); (q22; q22.1); RUNX1-RUNX1T1 / Adult Acute Myeloid Leukemia With t(9;11)(p22.3;q23.3); MLLT3-KMT2A / Adult Acute Myeloid Leukemia With t(9;11)(p22;q23); MLLT3-MLL / Leukemia Acute Myeloid Leukemia (AML) / Untreated Adult Acute Myeloid Leukemia1
2Active Not RecruitingTreatmentAdult Acute Basophilic Leukemia / Adult Acute Eosinophilic Leukemia / Adult Acute Monoblastic Leukemia / Adult Acute Monocytic Leukemia / Adult Acute Myeloid Leukemia With Maturation / Adult Acute Myeloid Leukemia With t(9;11)(p22.3;q23.3); MLLT3-KMT2A / Adult Acute Myeloid Leukemia With t(9;11)(p22;q23); MLLT3-MLL / Adult Acute Myeloid Leukemia Without Maturation / Adult Acute Myelomonocytic Leukemia / Alkylating Agent-Related Acute Myeloid Leukemia / Leukemia Acute Myeloid Leukemia (AML) / Secondary Acute Myeloid Leukemia / Untreated Adult Acute Myeloid Leukemia1
2Active Not RecruitingTreatmentChronic Myelomonocytic Leukemia1
2Active Not RecruitingTreatmentLeukemia Acute Myeloid Leukemia (AML)3
2Active Not RecruitingTreatmentLeukemias4
2Active Not RecruitingTreatmentMyelodysplastic Syndrome1
2Active Not RecruitingTreatmentPrimary Myelofibrosis / Secondary Myelofibrosis1
2CompletedNot AvailableChronic Myelomonocytic Leukemia1
2CompletedBasic ScienceLeukemia Acute Myeloid Leukemia (AML) / Myelodysplastic Syndromes / Myeloproliferative Neoplasms / Myeloproliferative/Myelodysplastic Neoplasm1
2CompletedSupportive CareMyelodysplastic Syndromes / Smith-Magenis Syndrome / Thrombocytopenias1
2CompletedTreatmentAccelerated Phase Chronic Myelogenous Leukemia / Blastic Phase Chronic Myelogenous Leukemia / Childhood Chronic Myelogenous Leukemia / Chronic Myelogenous Leukemia, BCR-ABL1 Positive / Relapsing Chronic Myelogenous Leukemia1
2CompletedTreatmentAcute Myelogenous Leukaemia (AML) / Myelodysplastic Syndrome4
2CompletedTreatmentAcute Myeloid Leukemia With Multilineage Dysplasia / Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome / Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Del(5q) / Adult Acute Myeloid Leukemia With T(15;17)(q22;q12) / De Novo Myelodysplastic Syndromes / Previously Treated Myelodysplastic Syndromes / Secondary Acute Myeloid Leukemia / Secondary Myelodysplastic Syndromes / Untreated Adult Acute Myeloid Leukemia1
2CompletedTreatmentAdult Acute Megakaryoblastic Leukemia (M7) / Adult Acute Monoblastic Leukemia (M5a) / Adult Acute Monocytic Leukemia (M5b) / Adult Acute Myeloblastic Leukemia With Maturation (M2) / Adult Acute Myeloblastic Leukemia Without Maturation (M1) / Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Del(5q) / Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Acute Myeloid Leukemia With T(8;21)(q22;q22) / Adult Acute Myelomonocytic Leukemia (M4) / Adult Erythroleukemia (M6a) / Adult Pure Erythroid Leukemia (M6b) / Previously Treated Myelodysplastic Syndromes / Recurrent Adult Acute Myeloid Leukemia / Refractory Anemia With Excess Blasts1
2CompletedTreatmentAdult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Del(5q) / Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) / Adult Acute Myeloid Leukemia With T(15;17)(q22;q12) / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Acute Myeloid Leukemia With T(8;21)(q22;q22) / Secondary Acute Myeloid Leukemia / Untreated Adult Acute Myeloid Leukemia1
2CompletedTreatmentChronic Myelogenous Leukemia (CML)3
2CompletedTreatmentChronic Myelomonocytic Leukemia / Myelodysplastic Syndrome1
2CompletedTreatmentLeukemia Acute Myeloid Leukemia (AML)3
2CompletedTreatmentLeukemia Acute Myeloid Leukemia (AML) / Myelodysplastic Syndrome1
2CompletedTreatmentLeukemias / Myelodysplastic Syndromes1
2CompletedTreatmentMyelodysplastic Syndrome5
2CompletedTreatmentMyelodysplastic Syndrome / Smith-Magenis Syndrome1
2CompletedTreatmentNeutropenias / Sickle Cell Disorders1
2CompletedTreatmentPediatric Acute Myelogenous Leukemia (AML)1
2CompletedTreatmentRecurrent Thyroid Cancer / Stage IVA Follicular Thyroid Cancer / Stage IVA Papillary Thyroid Cancer / Stage IVB Follicular Thyroid Cancer / Stage IVB Papillary Thyroid Cancer / Stage IVC Follicular Thyroid Cancer / Stage IVC Papillary Thyroid Cancer1
2CompletedTreatmentThalassaemic disorders1
2Not Yet RecruitingTreatmentNeoplasms, Breast1
2RecruitingTreatmentAcute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome / Chronic Myelomonocytic Leukemia / Previously Treated Myelodysplastic Syndromes / Recurrent Acute Myeloid Leukemia With Myelodysplasia-Related Changes / Recurrent Adult Acute Myeloid Leukemia1
2RecruitingTreatmentAcute Myeloid Leukemia With FLT3/ITD Mutation / Acute Myeloid Leukemia With Gene Mutations / FLT3 Tyrosine Kinase Domain Point Mutation / Secondary Acute Myeloid Leukemia / Untreated Adult Acute Myeloid Leukemia1
2RecruitingTreatmentAcute Myeloid Leukemia, Relapsed, Adult / Leukemia Acute Myeloid Leukemia (AML)1
2RecruitingTreatmentAdult Acute Myeloid Leukemia / Adult Myelodysplastic Syndrome / Secondary Acute Myeloid Leukemia / Therapy-Related Acute Myeloid Leukemia1
2RecruitingTreatmentAdvanced Non-Small Cell Lung Cancer / Lung Cancer Non-Small Cell Cancer (NSCLC) / Lung Cancers1
2RecruitingTreatmentBreast Adenocarcinoma / Breast Cancer Metastatic / Breast Cancer Stage II / Breast Cancer Stage III / Estrogen Receptor- Negative Breast Cancer / Estrogen Receptor-Positive Breast Cancer / HER2/Neu Negative / Invasive Adenocarcinoma of the Breast / Invasive Breast Carcinoma / Locally Advanced Breast Cancer (LABC) / Progesterone Receptor Negative / Progesterone Receptor Positive Tumor / Stage II Breast Cancer / Stage IIA Breast Cancer / Stage IIB Breast Cancer / Stage IIIA Breast Cancer / Stage IIIB Breast Cancer / Triple-Negative Breast Carcinoma1
2RecruitingTreatmentChronic Myelomonocytic Leukemia / Leukemia Acute Myeloid Leukemia (AML) / Myelodysplastic Syndrome1
2RecruitingTreatmentChronic Myelomonocytic Leukemia / De Novo Myelodysplastic Syndrome / Secondary Myelodysplastic Syndromes1
2RecruitingTreatmentComplex Karyotype / Leukemia Acute Myeloid Leukemia (AML)1
2RecruitingTreatmentImmune Thrombocytopenia1
2RecruitingTreatmentLeukemia Acute Myeloid Leukemia (AML)3
2RecruitingTreatmentLeukemia Acute Myeloid Leukemia (AML) / Myelodysplastic Syndromes2
2RecruitingTreatmentLeukemias4
2RecruitingTreatmentMyelodysplastic Syndromes1
2TerminatedTreatmentAcute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome / Adult Acute Megakaryoblastic Leukemia (M7) / Adult Acute Minimally Differentiated Myeloid Leukemia (M0) / Adult Acute Monoblastic Leukemia (M5a) / Adult Acute Monocytic Leukemia (M5b) / Adult Acute Myeloblastic Leukemia With Maturation (M2) / Adult Acute Myeloblastic Leukemia Without Maturation (M1) / Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Del(5q) / Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Acute Myeloid Leukemia With T(8;21)(q22;q22) / Adult Acute Myelomonocytic Leukemia (M4) / Adult Erythroleukemia (M6a) / Adult Pure Erythroid Leukemia (M6b) / Secondary Acute Myeloid Leukemia / Untreated Adult Acute Myeloid Leukemia1
2TerminatedTreatmentCancer, Ovarian / Fallopian Tube Cancer / Peritoneal Cavity Cancer1
2TerminatedTreatmentChronic Myelomonocytic Leukemia / Myelodysplastic Syndrome1
2TerminatedTreatmentChronic Myeloproliferative Disorders / Secondary Myelofibrosis1
2TerminatedTreatmentLeukemias1
2TerminatedTreatmentLeukemias / Malignant Lymphomas1
2TerminatedTreatmentMyelodysplastic Syndrome1
2TerminatedTreatmentRenal Cell Adenocarcinoma1
2Unknown StatusTreatmentChronic Myelomonocytic Leukemia / Leukemia Acute Myeloid Leukemia (AML) / Myelodysplastic Syndrome1
2WithdrawnTreatmentMelanoma1
2, 3CompletedTreatmentAcute Myelogenous Leukaemia (AML)1
2, 3Not Yet RecruitingTreatmentAdult Myelodysplastic Syndrome / Leukemia Acute Myeloid Leukemia (AML) / Myelodysplastic Syndrome With Excess Blasts-2 / Untreated Adult Acute Myeloid Leukemia1
2, 3RecruitingTreatmentAllogeneic peripheral haematopoietic stem cell transplant / Conditioning / Myelodysplastic Syndrome1
2, 3RecruitingTreatmentFIGO Stages II to IV / Primary Malignant Neoplasm of Ovary1
2, 3Unknown StatusTreatmentAcute Myelocytic Leukemia / Myelodysplastic Syndromes1
2, 3Unknown StatusTreatmentMyelodysplastic Syndromes1
3Active Not RecruitingTreatmentLeukemia Acute Myeloid Leukemia (AML)1
3CompletedTreatmentLeukemia Acute Myeloid Leukemia (AML)1
3CompletedTreatmentMyelodysplastic Syndrome1
3Enrolling by InvitationTreatmentAdult Acute Myeloid Leukemia1
3No Longer AvailableNot AvailableMyelodysplastic Syndromes1
3Not Yet RecruitingTreatmentChronic Myelomonocytic Leukemia / Myelodysplastic Syndromes1
3Not Yet RecruitingTreatmentHematologic Diseases / Thrombocytopenias1
3Not Yet RecruitingTreatmentImmune Thrombocytopenia / Purpura, Thrombocytopenic, Idiopathic1
3RecruitingTreatmentAcute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome / Adult Acute Megakaryoblastic Leukemia (M7) / Adult Acute Minimally Differentiated Myeloid Leukemia (M0) / Adult Acute Monoblastic Leukemia (M5a) / Adult Acute Monocytic Leukemia (M5b) / Adult Acute Myeloblastic Leukemia With Maturation (M2) / Adult Acute Myeloblastic Leukemia Without Maturation (M1) / Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Del(5q) / Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Acute Myeloid Leukemia With T(8;21)(q22;q22) / Adult Acute Myelomonocytic Leukemia (M4) / Adult Erythroleukemia (M6a) / Adult Pure Erythroid Leukemia (M6b) / Secondary Acute Myeloid Leukemia / Untreated Adult Acute Myeloid Leukemia1
3RecruitingTreatmentLeukemia Acute Myeloid Leukemia (AML)2
3RecruitingTreatmentLeukemias1
3RecruitingTreatmentSmith-Magenis Syndrome1
3Unknown StatusTreatmentDrug Safety / Effect of Drugs / Untreated Adult Acute Myeloid Leukemia1
3Unknown StatusTreatmentLeukemia Acute Myeloid Leukemia (AML)1
3Unknown StatusTreatmentLeukemias / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Neoplasms1
4Active Not RecruitingPreventionLeukemia Acute Myeloid Leukemia (AML)1
4CompletedNot AvailableMyelodysplastic Syndrome1
4CompletedNot AvailableMyelodysplastic Syndromes1
4TerminatedTreatmentMyelodysplastic Syndromes1
4Unknown StatusTreatmentHigher-risk Myelodysplastic Syndrome / Relapsed /Refractory Acute Myeloid Leukemia1
4Unknown StatusTreatmentMyelodysplastic Syndrome1
Not AvailableActive Not RecruitingTreatmentChronic Myelomonocytic Leukemia-2 / Myelodysplastic Syndrome / Myeloproliferative Neoplasms / Untreated Adult Acute Myeloid Leukemia1
Not AvailableCompletedNot AvailableAcute iron intoxication / Beta-Thalassemia / Bone destruction / Hematologic Diseases / Pulmonary Hypertension (PH) / Thalassaemic disorders / Thalassemia Major (TM)1
Not AvailableNot Yet RecruitingNot AvailableElderly / Intensive Chemotherapy Unfit / Leukemia Acute Myeloid Leukemia (AML)1
Not AvailableNot Yet RecruitingTreatmentMalignant Neoplasm of Pancreas1
Not AvailableRecruitingNot AvailableMalignant Neoplasm of Colon1
Not AvailableRecruitingTreatmentAdult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Del(5q) / Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) / Adult Acute Myeloid Leukemia With T(15;17)(q22;q12) / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Acute Myeloid Leukemia With T(8;21)(q22;q22) / Recurrent Adult Acute Myeloid Leukemia / Secondary Acute Myeloid Leukemia1
Not AvailableRecruitingTreatmentMyelodysplastic Syndromes (MDS)1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Dosage forms
FormRouteStrength
Injection, powder, for solutionIntravenous50 mg
Injection, powder, lyophilized, for solutionIntravenous50 mg/20mL
Injection, powder, lyophilized, for solutionIntravenous50 mg/50mL
Kit
Prices
Unit descriptionCostUnit
Dacogen 50 mg vial1706.4USD vial
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
water solubilitySparingly solubleNot Available
Predicted Properties
PropertyValueSource
Water Solubility5.5 mg/mLALOGPS
logP-2ALOGPS
logP-2.2ChemAxon
logS-1.6ALOGPS
pKa (Strongest Acidic)13.89ChemAxon
pKa (Strongest Basic)-0.25ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count7ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area120.74 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity50.68 m3·mol-1ChemAxon
Polarizability21.15 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9862
Blood Brain Barrier+0.8787
Caco-2 permeable-0.8362
P-glycoprotein substrateNon-substrate0.7192
P-glycoprotein inhibitor INon-inhibitor0.9216
P-glycoprotein inhibitor IINon-inhibitor0.953
Renal organic cation transporterNon-inhibitor0.8791
CYP450 2C9 substrateNon-substrate0.8359
CYP450 2D6 substrateNon-substrate0.8511
CYP450 3A4 substrateNon-substrate0.5356
CYP450 1A2 substrateNon-inhibitor0.9276
CYP450 2C9 inhibitorNon-inhibitor0.9265
CYP450 2D6 inhibitorNon-inhibitor0.9446
CYP450 2C19 inhibitorNon-inhibitor0.9379
CYP450 3A4 inhibitorNon-inhibitor0.9635
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9629
Ames testNon AMES toxic0.588
CarcinogenicityNon-carcinogens0.8109
BiodegradationNot ready biodegradable0.8957
Rat acute toxicity1.9436 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9654
hERG inhibition (predictor II)Non-inhibitor0.8972
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as triazinones. These are compounds containing a triazine ring which bears a ketone group a carbon atom.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Triazines
Sub Class
Triazinones
Direct Parent
Triazinones
Alternative Parents
Aminotriazines / 1,3,5-triazines / Tetrahydrofurans / Heteroaromatic compounds / Secondary alcohols / Oxacyclic compounds / Azacyclic compounds / Primary amines / Primary alcohols / Organopnictogen compounds
show 2 more
Substituents
Amino-1,3,5-triazine / Aminotriazine / Triazinone / 1,3,5-triazine / Tetrahydrofuran / Heteroaromatic compound / Secondary alcohol / Oxacycle / Azacycle / Organic oxide
show 11 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
2'-deoxyribonucleoside (CHEBI:50131)

Targets

1. DNA
Kind
Nucleotide
Organism
Human
Pharmacological action
Yes
Actions
Other/unknown
General Function:
Used for biological information storage.
Specific Function:
DNA contains the instructions needed for an organism to develop, survive and reproduce.
Molecular Weight:
2.15 x 1012 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  3. Appleton K, Mackay HJ, Judson I, Plumb JA, McCormick C, Strathdee G, Lee C, Barrett S, Reade S, Jadayel D, Tang A, Bellenger K, Mackay L, Setanoians A, Schatzlein A, Twelves C, Kaye SB, Brown R: Phase I and pharmacodynamic trial of the DNA methyltransferase inhibitor decitabine and carboplatin in solid tumors. J Clin Oncol. 2007 Oct 10;25(29):4603-9. [PubMed:17925555]
  4. Atallah E, Kantarjian H, Garcia-Manero G: The role of decitabine in the treatment of myelodysplastic syndromes. Expert Opin Pharmacother. 2007 Jan;8(1):65-73. [PubMed:17163808]
  5. Jabbour E, Issa JP, Garcia-Manero G, Kantarjian H: Evolution of decitabine development: accomplishments, ongoing investigations, and future strategies. Cancer. 2008 Jun;112(11):2341-51. doi: 10.1002/cncr.23463. [PubMed:18398832]
  6. Stresemann C, Lyko F: Modes of action of the DNA methyltransferase inhibitors azacytidine and decitabine. Int J Cancer. 2008 Jul 1;123(1):8-13. doi: 10.1002/ijc.23607. [PubMed:18425818]
  7. Oki Y, Aoki E, Issa JP: Decitabine--bedside to bench. Crit Rev Oncol Hematol. 2007 Feb;61(2):140-52. Epub 2006 Oct 4. [PubMed:17023173]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Zinc ion binding
Specific Function
Methylates CpG residues. Preferentially methylates hemimethylated DNA. Associates with DNA replication sites in S phase maintaining the methylation pattern in the newly synthesized strand, that is ...
Gene Name
DNMT1
Uniprot ID
P26358
Uniprot Name
DNA (cytosine-5)-methyltransferase 1
Molecular Weight
183163.635 Da
References
  1. Ando T, Nishimura M, Oka Y: Decitabine (5-Aza-2'-deoxycytidine) decreased DNA methylation and expression of MDR-1 gene in K562/ADM cells. Leukemia. 2000 Nov;14(11):1915-20. [PubMed:11069027]
  2. Karpf AR, Moore BC, Ririe TO, Jones DA: Activation of the p53 DNA damage response pathway after inhibition of DNA methyltransferase by 5-aza-2'-deoxycytidine. Mol Pharmacol. 2001 Apr;59(4):751-7. [PubMed:11259619]
  3. Csankovszki G, Nagy A, Jaenisch R: Synergism of Xist RNA, DNA methylation, and histone hypoacetylation in maintaining X chromosome inactivation. J Cell Biol. 2001 May 14;153(4):773-84. [PubMed:11352938]
  4. Takebayashi S, Nakao M, Fujita N, Sado T, Tanaka M, Taguchi H, Okumura K: 5-Aza-2'-deoxycytidine induces histone hyperacetylation of mouse centromeric heterochromatin by a mechanism independent of DNA demethylation. Biochem Biophys Res Commun. 2001 Nov 9;288(4):921-6. [PubMed:11688997]
  5. Saunthararajah Y, Hillery CA, Lavelle D, Molokie R, Dorn L, Bressler L, Gavazova S, Chen YH, Hoffman R, DeSimone J: Effects of 5-aza-2'-deoxycytidine on fetal hemoglobin levels, red cell adhesion, and hematopoietic differentiation in patients with sickle cell disease. Blood. 2003 Dec 1;102(12):3865-70. Epub 2003 Aug 7. [PubMed:12907443]
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
  7. Daskalakis M, Blagitko-Dorfs N, Hackanson B: Decitabine. Recent Results Cancer Res. 2010;184:131-57. doi: 10.1007/978-3-642-01222-8_10. [PubMed:20072836]
  8. Saba HI, Wijermans PW: Decitabine in myelodysplastic syndromes. Semin Hematol. 2005 Jul;42(3 Suppl 2):S23-31. [PubMed:16015501]
  9. Jabbour E, Issa JP, Garcia-Manero G, Kantarjian H: Evolution of decitabine development: accomplishments, ongoing investigations, and future strategies. Cancer. 2008 Jun;112(11):2341-51. doi: 10.1002/cncr.23463. [PubMed:18398832]
  10. Stresemann C, Lyko F: Modes of action of the DNA methyltransferase inhibitors azacytidine and decitabine. Int J Cancer. 2008 Jul 1;123(1):8-13. doi: 10.1002/ijc.23607. [PubMed:18425818]
  11. Oki Y, Aoki E, Issa JP: Decitabine--bedside to bench. Crit Rev Oncol Hematol. 2007 Feb;61(2):140-52. Epub 2006 Oct 4. [PubMed:17023173]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Protein homodimerization activity
Specific Function
Required for the phosphorylation of the deoxyribonucleosides deoxycytidine (dC), deoxyguanosine (dG) and deoxyadenosine (dA). Has broad substrate specificity, and does not display selectivity based...
Gene Name
DCK
Uniprot ID
P27707
Uniprot Name
Deoxycytidine kinase
Molecular Weight
30518.315 Da
References
  1. Schwarzenberg J, Radu CG, Benz M, Fueger B, Tran AQ, Phelps ME, Witte ON, Satyamurthy N, Czernin J, Schiepers C: Human biodistribution and radiation dosimetry of novel PET probes targeting the deoxyribonucleoside salvage pathway. Eur J Nucl Med Mol Imaging. 2011 Apr;38(4):711-21. doi: 10.1007/s00259-010-1666-z. Epub 2010 Dec 3. [PubMed:21127859]

Drug created on May 16, 2007 11:38 / Updated on November 09, 2017 02:58